NCT05864599View on ClinicalTrials.gov

External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the CUETO Group

Active, not recruitingOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

June 30, 2024

Conditions
Non-muscle-invasive Bladder Cancer
Trial Locations (1)

46015

Hospital Vithas 9 d'Octubre, Valencia

Sponsors

Lead Sponsor

Pharmalink
All Listed Sponsors
lead

Pharmalink

INDUSTRY